Findings

YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial

- Company Announces Lead Investigator for U.S. Trial - MISSISSAUGA, ON, July 11, 2007 /PRNewswire-FirstCall/ - YMBioSciences Inc. , an oncology company that identifies, developsand commercializes differentiated products for patients worldwide,today announced results of secondary endpoint data from its 99patient, randomized, placebo-controlled, multi-center Phase IIbtrial (DLXLEF-AP4) with...

BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Jul 11, 2007 - BioSantePharmaceuticals, Inc. (Amex: BPA) today announced new positiveresults demonstrating that its calcium phosphate (CaP)nanoparticle-based vaccine adjuvant, BioVant(TM), may serve as aneffective vaccine adjuvant for the development of a dose sparingvaccine against H5N1 avian flu, widely known as bird flu. The new results are based on...

Molecular Target of Bradmer's Neuradiab Further Validated by Independent Findings

TSX: BMR TORONTO, July 10, 2007 /PRNewswire-FirstCall/ - BradmerPharmaceuticals Inc., a biopharmaceutical company dedicated to thedevelopment and commercialization of cancer therapies, todayannounced that new research published by an independent team inBasel, Switzerland validates tenascin as an important moleculartarget for the development of new treatments for glioblastomamultiforme (G...

Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science

- Journal Article Also Demonstrates the Promise of Anacor'sBoron-Based Chemistry in Developing Antibiotics - PALO ALTO, Calif., June 21, 2007 /PRNewswire/ -- AnacorPharmaceuticals, a privately held pharmaceutical company, announcedtoday that the journal Science will publish results of researchthat details how AN2690, the company's lead clinical candidate,kills fungal cells by interfering...

Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study

YONKERS, N.Y.--(BUSINESS WIRE)--Jun 18, 2007 - Advanced ViralResearch Corp. (OTCBB: ADVR), a research based biopharmaceuticalcompany, announced today that preliminary findings from its ongoingPhase II dermatological study show topical treatment with AVR118appears to have clinical activity in reducing inflammation andredness associated with surgical incisions or dermatologicdermabrasion....

Haemacure Announces Preliminary Findings of its Plasma Discard Analysis

MONTREAL, June 14, 2007 /PRNewswire-FirstCall/ HaemacureCorporation , a Montreal-based specialty biotherapeutics company,today announced the preliminary findings of the content analysis ofone of its plasma discards. Preliminary findings confirm the presence of a number ofproteins and enzymes with applications in significant worldwidemarkets, including albumin, plasmi...

EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3 Clinical Trial at 47th Annual NCDEU Meeting

LEXINGTON, Mass.--(BUSINESS WIRE)--Jun 13, 2007 - EPIXPharmaceuticals, Inc. (NASDAQ: EPIX) today announced that data fromits Phase 3 trial of PRX-00023, a novel long-acting 5-HT1A agonist,was featured in a poster presentation at the 47th Annual NewClinical Drug Evaluation Unit (NCDEU) Meeting in Boca Raton,Florida. The meeting is sponsored by the National Institutes ofHealth and the America...

Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune Deficiency

THE WOODLANDS, Texas, June 08, 2007 /PRNewswire-FirstCall/ --Lexicon Pharmaceuticals, Inc. today announced the publication ofnew findings from a joint research project with scientists at FoxChase Cancer Center in Philadelphia, PA. Together with David L.Wiest, Ph.D., Lexicon researchers have discovered a novel andsurprising role for ribosomal protein L22 (Rpl22) in thedevelopment of T lym...

Prana Biotechnology Presents New Key Findings on PBT2

PBT2 Alters Biomarkers and Rapidly Improves Cognition in twodistinct models of Alzheimer's Disease MELBOURNE, Australia - June 7, 2007 - Prana BiotechnologyLimited (NASDAQ: PRAN / ASX: PBT), a biopharmaceutical companyfocused on the research and development of treatments forneurodegenerative disorders, announced today that it will presentnew data on Prana's lead Alzheimer's disease (AD) d...

Investigation Findings, Corroborated by Empirical Evidence of the Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine for Hundreds of Years, Support the Use of Schisandrin B in the Prevention and Treatment of IHD

SEATTLE--(BUSINESS WIRE)--May 29, 2007 - Mitopharm Corporation,Inc. (Pink Sheets:MTPM), releases the results of a research paperwhere Professor Dr. Robert Ko published the beneficial effects ofSchisandrin B, the precursor of (-) Schisandrin B - a noveldiscovery by Dr. Ko - on Ischemic Heart Disease. In a research paper entitled "SCHISANDRIN B PROTECTS AGAINSTMYOCARDIAL ISCHEMIA-REPERFUSIO...

ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 24, 2007 - ImmunoGen, Inc.(Nasdaq: IMGN), a biopharmaceutical company that develops targetedanticancer therapeutics using its Tumor-Activated Prodrug (TAP)technology, today announced that clinical findings for threedifferent TAP compounds for the treatment of solid tumors are to bereported at the 43rd American Society of Clinical Oncology (ASCO)Annual...

Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth

LIVINGSTON, N.J.--(BUSINESS WIRE)--Apr 26, 2007 - ColumbiaLaboratories, Inc. (NASDAQ: CBRX) today announced that preliminaryresults from the ongoing data analysis of the recently-completedrandomized, placebo-controlled, double-blind Phase III clinicaltrial of PROCHIEVE(R) 8% (progesterone gel) for the prevention ofpreterm birth in women with a previous preterm birth earlier than35 weeks ges...

Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway

LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScience,Inc. (NASDAQ:ABBI), an integrated, global biopharmaceuticalcompany, announced results from two pre-clinical studies thatsupport the role of SPARC (secreted protein acidic and rich incysteine) expression in cancer and Abraxis' nanoparticlealbumin-bound (nab(TM)) tumor-targeting technology at the 98thAmerican Association for Canc...

Bionovo to Present Recent Findings of BZL101, Its Anti-cancer Agent, at the American Association of Cancer Research

EMERYVILLE, Calif., April 16, 2007 /PRNewswire-FirstCall/ --Bionovo, Inc. will present findings on the mechanism of action ofits anti-cancer agent BZL101, which is advancing to Phase 1/2clinical testing for late stage breast cancer at the AmericanAssociation of Cancer Research (AACR) being held at the Los AngelesConvention Center in Los Angeles, CA, April 14 - 17, 2007. Bionovo's p...

Pivotal Phase III Findings With Investigational Drug Cleviprex (Clevidipine) Demonstrate Perioperative Blood Pressure Control In Cardiac Surgery

First Presentation of Comparative Data from ECLIPSE, Largest SafetyProgram of Intravenous Antihypertensive Agents NEW ORLEANS, March 27, 2007 /PRNewswire-FirstCall/ -- Favorablefindings of the investigational drug Cleviprex(TM) (clevidipine)compared to current intravenous antihypertensive agents incontrolling perioperative hypertension -- a potentially harmfulelevation in blood pressure j...

Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery

Largest Randomized Safety Program of Intravenous Antihypertensivesto Date Presented at ACC Scientific Sessions NEW ORLEANS, March 27, 2007 /PRNewswire-FirstCall/ -- Findingsfrom ECLIPSE**, the largest safety program comparing intravenousantihypertensive therapies, show that improved control ofperioperative hypertension -- a potentially harmful elevation inblood pressure just before, durin...

Acuity One-Year Findings Meet All Primary Endpoints in Favor of Angiomax (Bivalirudin) Alone Treatment Group

Major Bleeding in Patients Treated for Acute Coronary Syndromes(ACS) Nearly Triples the Risk of Death at One Year NEW ORLEANS, March 26, 2007 /PRNewswire/ -- One-year findingsfrom the landmark ACUITY trial show that acute coronary syndrome(ACS) patients in the "Angiomax(R) (bivalirudin) alone" treatmentgroup had similar rates of ischemic clinical outcomes compared withmore complicated sta...

DVT Awareness Survey Findings for Respondents in High-Risk Groups: Obese Individuals

WASHINGTON, March 15, 2007 /PRNewswire/ -- Up to two millionAmericans are affected each year by DVT, with up to 600,000hospitalized. Its primary complication, pulmonary embolism (PE),claims up to 300,000 lives annually -- more than breast cancer andAIDS combined. The Coalition to Prevent Deep-Vein Thrombosis (DVT) recentlysponsored an online survey of a nationally representative sa...

DVT Awareness Survey Findings: Heart and Respiratory Patients

WASHINGTON, March 06, 2007 /PRNewswire/ -- Up to two millionAmericans are affected each year by DVT, with up to 600,000hospitalized. Its primary complication, pulmonary embolism (PE),claims up to 300,000 lives annually -- more than breast cancer andAIDS combined. People who suffer from cardiovascular disease may beat increased risk for DVT, because these factors also heighten thelikeliho...

Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at the Fourth International Conference on Tumor Microenvironment in Florence, Italy

- Helix BioPharma Corp. (TSX: HBP /Frankfurt: WKN918864) AURORA, ON, March 5 /CNW/Dr. Heman Chao, Vice President of Researchat Helix BioPharma Corp., a developer of novel cancer therapeutics,will be presenting a scientific poster at the Fourth InternationalConference on Tumor Microenvironment, which runs from March 6th to10th in Florence, Italy. The conf...